The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis

British Journal of Radiology

Volumn 87, Issue 1038, 2014, Pages

  Chowdhury, R ^a,b   Ganeshan, B ^c   Irshad, S ^d   Lawler, K ^a   Eisenblatter M ^a,e   Milewicz, H ^f   Rodriguez Justo, M ^g   Miles, K ^c   Ellis, P ^a,b   Groves, A ^c   Punwani, S ^c   Ng, T ^a,d,f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e Rayne Institute   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE C 11; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; NANOPARTICLE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; TUMOR MARKER;

ALGORITHM; CANCER THERAPY; CELL HETEROGENEITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXOSOME; FLUORESCENCE IMAGING; GENOMICS; HUMAN; IN VITRO STUDY; INTRAOPERATIVE PERIOD; METASTASIS; METASTASIS POTENTIAL; MOLECULAR IMAGING; NANOIMAGING; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIMARY TUMOR; REVIEW; CELL TRANSFORMATION; DIAGNOSTIC IMAGING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASM METASTASIS; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; TUMOR MICROENVIRONMENT;

CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSTIC IMAGING; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84907516263     PISSN: 00071285     EISSN: 1748880X     Source Type: Journal    
DOI: 10.1259/bjr.20140065     Document Type: Review

References (129)

1. Fruhwirth GO, Fernandes LP, Weitsman G, Patel G, Kelleher M, Lawler K, et al. How Förster resonance energy transfer imaging improves the understanding of protein interaction networks in cancer biology. Chemphyschem 2011;12:442-61.
2. Virchow R. Die cellular pathologie in ihrer begründung auf physiologische und pathologische gewebelehre. Berlin, Germany: August Hirschwald; 1858.
3. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90-4. doi: 10.1038/nature09807
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92. doi: 10.1056/NEJMoa1113205
5. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.
6. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009;9:285-93.
7. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68.
8. Patel GS, Kiuchi T, Lawler K, Ofo E, Fruhwirth GO, Kelleher M, et al. The challenges of integrating molecular imaging into the optimization of cancer therapy. Integr Biol (Camb) 2011;3:603-31. doi: 10.1039/c0ib00131g
9. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-13. doi: 10.1038/nature08489
10. Hoefnagel LD, van der Groep P, van de Vijver MJ, Boers JE, Wesseling P, Wesseling J, et al. Discordance in ERa, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Ann Oncol 2013;24:3017-23.
11. Gaertner FC, Fürst S, Schwaiger M. PET/MR: a paradigm shift. Cancer Imaging 2013;13:36-52.
12. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
13. Huyge V, Garcia C, Alexiou J, Ameye L, Vanderlinden B, Lemort M, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol) 2010;22:818-27. doi: 10.1016/j.clon.2010.05.021
14. Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA. Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology 2013;266:326-36.
15. Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol 2012;22:796-802. doi: 10.1007/s00330-011-2319-8
16. Ganeshan B, Abaleke S, Young R C D, Chatwin CR, Miles KA. Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging 2010;10:137-43.
17. Ganeshan B, Miles KA, Young R C D, Chatwin CR. Hepatic enhancement in colorectal cancer: texture analysis correlates with hepatic hemodynamics and patient survival. Acad Radiol 2007;14:1520-30. doi: 10.1016/j.acra.2007.06.028
18. Miles KA, Ganeshan B, Griffiths MR, Young RC, Chatwin CR. Colorectal cancer: texture analysis of portal phase hepatic CT images as a potential marker of survival. Radiology 2009;250:444-52. doi: 10.1148/radiol.2502071879
19. Ganeshan B, Miles KA, Young RC, Chatwin CR. In search of biologic correlates for liver texture on portal-phase CT. Acad Radiol 2007;14:1058-68. doi: 10.1016/j.acra.2007.05.023
20. Cheng NM, Dean Fang YH, Chang JT, Huang CG, Tsan DL, Ng SH, et al. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma. J Nucl Med 2013;54:1703-9.
21. Brown R, Zlatescu M, Sijben A, Roldan G, Easaw J, Forsyth P, et al. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 2008;14:2357-62. doi: 10.1158/1078-0432. CCR-07-1964
22. Foroutan P, Kreahling JM, Morse DL, Grove O, Lloyd MC, Reed D, et al. Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy. PLoS One 2013;8:e82875.
23. Miles KA, Ganeshan B, Hayball MP. CT texture analysis using the filtrationhistogram method: what do the measurements mean? Cancer Imaging 2013;13:400-6. doi: 10.1102/1470-7330.2013.9045
24. Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol 2012;67:157-64.
25. Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med 2013;54:19-26. doi: 10.2967/jnumed.112.107375
26. Fan X, River JN, Zamora M, Tarlo K, Kellar K, Rinker-Schaeffer C, et al. Differentiation of nonmetastatic and metastatic rodent prostate tumors with high spectral and spatial resolution MRI. Magn Reson Med 2001;45:1046-55.
27. Win T, Miles KA, Janes SM, Ganeshan B, Shastry M, Endozo R, et al. Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res 2013;19:3591-9. doi: 10.1158/1078-0432. CCR-12-1307
28. Tixier F, Hatt M, Le Rest CC, Le Pogam A, Corcos L, Visvikis D. Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET. J Nucl Med 2012;53:693-700.
29. Boothman DA, Davis TW, Sahijdak WM. Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1994;30:391-8.
30. Mirjolet JF, Barberi-Heyob M, Merlin JL, Marchal S, Etienne MC, Milano G, et al. Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. Br J Cancer 1998;78:62-8.
31. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003;52:1602-6.
32. Roger L, Gadea G, Roux P. Control of cell migration: a tumour suppressor function for p53? Biol Cell 2006;98:141-52.
33. Evdokimova V, Tognon C, Ng T, Sorensen PH. Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 2009;8:2901-6.
34. Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell 2013;155:750-64.
35. Troost E G C, Vogel WV, Merkx MA, Slootweg PJ, Marres HA, Peeters WJ, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007;48:726-35. doi: 10.2967/jnumed.106.037473
36. Troost EG, Bussink J, Oyen WJ, Kaanders JH. 18F-FDG and 18F-FLT do not discriminate between reactive and metastatic lymph nodes in oral cancer. J Nucl Med 2009;50:490-1. doi: 10.2967/jnumed.108.055962
37. Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and metaanalysis. Eur Urol 2013;64:106-17. doi: 10.1016/j.eururo.2013.04.019
38. Yang Z, Sun Y, Zhang Y, Xue J, Wang M, Shi W, et al. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo? Clin Breast Cancer 2013;13:359-63.
39. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 2008;14:459-65.
40. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003;17:509-20.
41. Metz S, Ganter C, Lorenzen S, van Marwick S, Herrmann K, Lordick F, et al. Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med 2010;51:1691-8.
42. Glaus C, Rossin R, Welch MJ, Bao G. In vivo evaluation of (64) Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug Chem 2010;21:715-22.
43. Fraioli F, Punwani S. Clinical and research applications of simultaneous positron emission tomography and MRI. Br J Radiol 2014;87:20130464. doi: 10.1259/bjr.20130464
44. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate cancer detection with multiparametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009;30:327-34.
45. Panebianco V, Barchetti F, Sciarra A, Musio D, Forte V, Gentile V, et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multiparametric magnetic resonance imaging. Eur Radiol 2013;23:1745-52.
46. Reiner CS, Stolzmann P, Husmann L, Burger IA, Hüllner MW, Schaefer NG, et al. Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection. Eur J Nucl Med Mol Imaging 2014;41:649-58. doi: 10.1007/s00259-013-2654-x
47. Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 2009;36(Suppl. 1):S113-20. doi: 10.1007/s00259-008-0951-6
48. Wiesmüller M, Quick HH, Navalpakkam B, Lell MM, Uder M, Ritt P, et al. Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT. Eur J Nucl Med Mol Imaging 2013;40:12-21. doi: 10.1007/s00259-012-2249-y
49. Chandarana H, Heacock L, Rakheja R, DeMello LR, Bonavita J, Block TK, et al. Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET/MR and PET/CT imaging. Radiology 2013;268:874-81. doi: 10.1148/radiol.13130620
50. Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Aoyama N, Onishi Y, et al. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. AJR Am J Roentgenol 2012;198:75-82.
51. Walker-Samuel S, Ramasawmy R, Torrealdea F, Rega M, Rajkumar V, Johnson SP, et al. In vivo imaging of glucose uptake and metabolism in tumors. Nat Med 2013;19:1067-72.
52. Golman K. Molecular imaging using hyperpolarized 13C. Br J Radiol 2003;76(Suppl. 2):S118-27.
53. Brindle KM, Bohndiek SE, Gallagher FA, Kettunen MI. Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopy. Magn Reson Med 2011;66:505-19.
54. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 2007;13:1382-7.
55. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci Transl Med 2013;5:198ra108. doi: 10.1126/scitranslmed.3006070
56. Chaumeil MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, et al. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroimage 2012;59:193-201.
57. Dafni H, Larson PE, Hu S, Yoshihara HA, Ward CS, Venkatesh HS, et al. Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. Cancer Res 2010;70:7400-10.
58. Hu S, Balakrishnan A, Bok RA, Anderton B, Larson PE, Nelson SJ, et al. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab 2011;14:131-42. doi: 10.1016/j.cmet.2011.04.012
59. Wolfer A, Ramaswamy S. MYC and metastasis. Cancer Res 2011;71:2034-7.
60. Berry CC, Curtis A S G. Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D: Appl Phys 2003;36:R198-206.
61. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16-20.
62. Sundstrøm T, Daphu I, Wendelbo I, Hodneland E, Lundervold A, Immervoll H, et al. Automated tracking of nanoparticlelabeled melanoma cells improves the predictive power of a brain metastasis model. Cancer Res 2013;73:2445-56.
63. Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 2010;30:15-35.
64. Sarikaya I, Povoski SP, Al-Saif OH, Kocak E, Bloomston M, Marsh S, et al. Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer. World J Surg Oncol 2007;5:80.
65. Epenetos AA, Kosmas C. Monoclonal antibodies for imaging and therapy. Br J Cancer 1989;59:152-5.
66. Nieroda CA, Mojzisik C, Sardi A, Ferrara PJ, Hinkle G, Thurston MO, et al. Radioimmunoguided surgery in primary colon cancer. Cancer Detect Prev 1990;14:651-6.
67. Nieroda CA, Mojzisik C, Hinkle G, Thurston MO, Martin EW. Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer. Cancer Detect Prev 1991;15:225-9.
68. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 2011;52:1778-85.
69. Van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-a targeting: first in-human results. Nat Med 2011;17:1315-19.
70. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res 2006;66:11089-93.
71. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005;438:820-7. doi: 10.1038/nature04186
72. Shokeen M, Zheleznyak A, Wilson JM, Jiang M, Liu R, Ferdani R, et al. Molecular imaging of very late antigen-4 (a4b1 integrin) in the premetastatic niche. J Nucl Med 2012;53:779-86. doi: 10.2967/jnumed.111.100073
73. Daldrup-Link H, Coussens LM. MR imaging of tumor-associated macrophages. Oncoimmunology 2012;1:507-9.
74. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21:154-65.
75. Obeid E, Nanda R, Fu YX, Olopade OI. The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol 2013;43:5-12.
76. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008;84:623-30.
77. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011;30:83-95.
78. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
79. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19. doi: 10.1200/JCO.2007.14.9930
80. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71.
81. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. doi: 10.1056/NEJMoa065044
82. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
83. Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, et al. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 2012;130:2359-65.
84. Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, et al. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced nonsmall-cell lung cancer receiving sorafenib. Clin Cancer Res 2011;17:1190-9. doi: 10.1158/1078-0432. CCR-10-2331
85. Barrera P, van der Laken CJ, Boerman OC, Oyen WJ, van de Ven MT, van Lent PL, et al. Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. Rheumatology 2000;39:870-4.
86. Barrera P, Oyen WJ, Boerman OC, van Riel PL. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:825-8.
87. Hiratsuka S, Ishibashi S, Tomita T, Watanabe A, Akashi-Takamura S, Murakami M, et al. Primary tumours modulate innate immune signalling to create pre-metastatic vascular hyperpermeability foci. Nat Commun 2013;4:1853.
88. Kiessling F, Farhan N, Lichy MP, Vosseler S, Heilmann M, Krix M, et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 2004;6:213-23.
89. Ehling J, Lammers T, Kiessling F. Noninvasive imaging for studying antiangiogenic therapy effects. Thromb Haemost 2013;109:375-90. doi: 10.1160/TH12-10-0721
90. Rafii S, Lyden D. S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol 2006;8:1321-3.
91. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-9.
92. Soekmadji C, Russell PJ, Nelson CC. Exosomes in prostate cancer: putting together the pieces of a puzzle. Cancers (Basel) 2013;5:1522-44.
93. Lorentzen E, Conti E. The exosome and the proteasome: nano-compartments for degradation. Cell 2006;125:651-4. doi: 10.1016/j.cell.2006.05.002
94. Makino DL, Halbach F, Conti E. The RNA exosome and proteasome: common principles of degradation control. Nat Rev Mol Cell Biol 2013;14:654-60.
95. Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 2010;9:1085-99. doi: 10.1074/mcp. M900381-MCP200
96. Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nat Med 2012;18:883-91.
97. Xiao D, Ohlendorf J, Chen Y, Taylor DD, Rai SN, Waigel S, et al. Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One 2012;7:e46874.
98. Rana S, Malinowska K, Zöller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013;15:281-95.
99. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 2013;91:431-7.
100. Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman RM. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev 2013;65:383-90. doi: 10.1016/j.addr.2012.08.007
101. Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 2009;4:e5219.
102. Bergmann C, Strauss L, Wieckowski E, Czystowska M, Albers A, Wang Y, et al. Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 2009;31:371-80.
103. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringnér M, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxiadependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A 2013;110:7312-17.
104. Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, Majeed F, et al. Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PLoS One 2013;8:e70047. doi: 10.1371/journal.pone.0070047
105. Camacho L, Guerrero P, Marchetti D. MicroRNA and protein profiling of brain metastasis competent cell-derived exosomes. PLoS One 2013;8:e73790. doi: 10.1371/journal.pone.0073790
106. Ji H, Greening DW, Barnes TW, Lim JW, Tauro BJ, Rai A, et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics 2013;13:1672-86.
107. Matusiak N, van Waarde A, Bischoff R, Oltenfreiter R, van de Wiele C, Dierckx RA, et al. Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT. Curr Pharm Des 2013;19:4647-72.
108. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL. Radiology 2012;263:663-72.
109. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100. doi: 10.1038/clpt.2009.68
110. Hylton N, Partridge S, Rosen M, Kim E, L'Heureux D, Esseman L. OT2-03-06: ACRIN 6698 MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: A Sub-Study of the I-SPY 2 TRIAL (Investigation of Serial Studies To Predict Your Therapeutic Response with Imaging And moLecular Analysis). Cancer Res 2012;71 (Suppl.).
111. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157.
112. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012;30:1996-2004. doi: 10.1200/JCO.2011.39.5624
113. Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004;31:1621-30.
114. Ignatius MS, Chen E, Elpek NM, Fuller AZ, Tenente IM, Clagg R, et al. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell 2012;21:680-93.
115. Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, et al. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One 2011;6:e28403.
116. Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007;25:675-80. doi: 10.1038/nbt1306
117. Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 2009;70:232-41.
118. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.
119. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
120. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell 2012;149:994-1007.
121. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012;18:4910-18.
122. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 2009;106:474-9. doi: 10.1073/pnas.0808930106
123. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87:586-92. doi: 10.1038/clpt.2010.12
124. Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med 2013;54:1869-75. doi: 10.2967/jnumed.112.118612
125. Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, et al. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Res 2013;73:6164-74.
126. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60. doi: 10.1126/science.1208130
127. Hofree M, Shen JP, Carter H, Gross A, Ideker T. Network-based stratification of tumor mutations. Nat Methods 2013;10:1108-15.
128. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40. doi: 10.1038/nature11219
129. Miles KA, Ganeshan B, Rodriguez-Justo M, Goh VJ, Ziauddin Z, Engledow A, et al. Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. J Nucl Med 2014;55:386-91. doi: 10.2967/jnumed.113.120485